Merck & Co is a general drug manufacturer company located in New Jersey, United States, which is part of the Healthcare sector, and is traded under the ticker MRK on the NYSE exchange.
Merck & Co stock last closed at $77.85, down 0.19% from the previous day, and has decreased 38.67% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.37 percentage points. Merck & Co stock is currently +2.53% from its 52-week low of $75.93, and -42.17% from its 52-week high of $134.63.
As of Apr 21, 2025, there are 2.53B MRK shares outstanding. The market cap of MRK is $196.65B. In the past 24 hours, 10.89M MRK shares were traded.
You need a brokerage account in order to access the NYSE market and buy MRK shares.
We believe that eToro is the best brokerage. Here's why:
Get $10 towards your stock purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've chosen the right brokerage, you need to fill out some personal details so you are able to invest in MRK today.
Now that you've opened your account on the best app for stock investing, you need to deposit funds:
Check out the walkthrough below for more details depositing money into your new brokerage account.
After you have figured out the best place to buy Merck & Co stock, it's critical to research their stock before you buy, so you can comprehend the risk and opportunity.
WallStreetZen was built to help part-time investors do more accurate fundamental analysis quickly.
You can view all of the due diligence checks on MRK's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge MRK's true value.
Using relative valuations ratios:
You can do additional valuation research on MRK's stock here.
Out of 11 sell side analysts who give ratings on MRK, the consensus analyst rating on Merck & Co is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Terence Flynn, a top 8% analyst from Morgan Stanley maintains MRK with a hold rating and lowers their MRK price target from $113.00 to $106.00, on Feb 5, 2025.
Morgan Stanley's Terence Flynn lowered their price target on Merck & Co (NYSE: MRK) by 6.2% from $113 to $106 on 2025/02/05. The analyst maintained their Hold rating on the stock.
Merck & Co. reported its Q4 and FY 2024 earnings.
Flynn blamed their price target cut on managment's below-consensus FY2025 guidance resulting from weak demand in China for Gardasil demand in China.
On that news, Morgan Stanley reduced its estimates on Merck & Co., but noted that "more broadly, the focus remains on the Keytrudatail/loss of exclusivity and the company's progress with its pipeline efforts."
Merck & Co. reported
For Q4 2024:
For FY 2024:
For FY 2025, management guided:
Chairman & CEO Robert M. Davis commented: “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, which continues to benefit more patients with cancer globally, the successful launch of WINREVAIR and strong performance of our Animal Health business.
"We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development.
"Our business remains well-positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential.”
Daina Graybosch, a bottom 2% analyst from Leerink Partners maintains MRK with a buy rating and lowers their MRK price target from $136.00 to $119.00, on Jan 13, 2025.
Colin Bristow, a bottom 7% analyst from UBS maintains MRK with a strong buy rating and lowers their MRK price target from $125.00 to $120.00, on Jan 8, 2025.
Robyn Karnauskas, a bottom 16% analyst from Truist Securities downgrades MRK to a hold rating and lowers their MRK price target from $130.00 to $110.00, on Jan 8, 2025.
Seamus Fernandez, a top 21% analyst from Guggenheim maintains MRK with a strong buy rating and lowers their MRK price target from $137.00 to $130.00, on Nov 6, 2024.
You can dig deeper into what analysts are projecting on the Merck & Co stock forecast page.
Last year, MRK earnings were $17.12B. Over the last five year, MRK's earnings have increased by 11.98% per year. This was faster than the Drug Manufacturers - General industry average of 0.89%.
Last year, MRK revenue was $64.17B. Over the past 5 year, MRK's revenue has grown by 10.4% per year. This was faster than the Drug Manufacturers - General industry average of 9.15%.
You can research MRK's earnings and revenue performance here.
In the past year, insiders at MRK have bought more shares than they have sold.
Johannes Jacobus Oosthuizen, President U.S. Market of MRK, was the latest MRK insider to sell. They sold $714,748.00 worth of MRK shares on Feb 19, 2025.
Get more info about who owns MRK stock here.
Merck & Co pays a dividend of 4.06%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.51%. If you owned $1,000 of MRK stock, you would have received $40.59 last year.
Merck & Co dividend payments have consistently grown over the past decade and have remained stable.
Dig into more data about Merck & Co dividend yield and history here.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
There are two main options:
Click the Open button and eToro will place the order.
If you need more help buying stocks on eToro, watch the helpful video below:
Now that you own some shares in MRK, you'll want to stay up-to-date on your stock purchase.
Make a watchlist to track the latest developments regarding your MRK stock.
To summarize, here are the 6 steps you need to take to buy Merck & Co stock right now:
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep track of your investment in Merck & Co, click the button below.